B

Bristol Myers Squibb

Makes drugs for cancer, blood and immune diseases

Vice President General Manager & Campus Lead

Full-TimeDeadline 11/1/26
$330.7k - $400.7k+ Discretionary incentive cash + Stock opportunities
Expert
Bachelor's, Master's, MBA, PhD
Devens, MA, USA
In Person
Business & Strategy
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • A bachelor's degree in Engineering, Life Sciences, Pharmacy, Biochemistry, or a related field is required.
  • Approximately 15+ years of progressive experience in pharmaceutical or biopharmaceutical manufacturing, with significant leadership in large-scale biologics drug substance operations.
  • A track record of leading large-scale organizational transformations or business unit integrations is required.
  • Deep knowledge of Good Manufacturing Practices and regulatory requirements, familiarity with Environmental, Health & Safety regulations and best practices for biologics and cell therapy manufacturing, and proven experience leading regulatory inspections and interacting with regulatory agencies.
  • Experience with large capital project planning and execution, including facility expansions or new production lines, and strong understanding of financial management processes and P&L responsibility for a manufacturing site or business unit.
  • Demonstrated expertise leading digitally and AI-driven transformations, including AI/ML implementation in manufacturing operations, digital twins and/or simulation technologies, predictive analytics, automation, and robotics.
  • Demonstrated ability to lead cross-functional, multicultural teams and develop high-performing organizations across multiple business units.
  • Experience managing multi-site or large, complex sites and understanding of the legal, cultural, and organizational nuances of leading in a global, matrixed environment.
  • Proven track record leading complex, multi-year organizational transformations and business unit integrations; ability to sequence change, manage ambiguity, and sustain safety, quality, and supply performance through disruption.
  • Ability to build unified governance and culture across previously separate organizations, align stakeholders around a shared campus vision, and balance enterprise priorities against individual business unit needs.
Responsibilities
  • Develop and execute Devens’ long-range strategy in alignment with BMS’s global manufacturing network, GBU pipeline plans, and Cell Therapy growth objectives.
  • Evolve the site’s capabilities to meet enterprise needs, including readiness for new biologics modalities and Cell Therapy platform expansion.
  • Represent Devens in Product Development and Supply and Cell Therapy governance forums and enterprise-wide manufacturing network forums, including Factory Level Optimized Work and best-practice standardization.
  • Anticipate industry trends and build site-level strategies and contingency plans for both business units.
  • Oversee GBU Biologics drug substance manufacturing operations at Devens to ensure reliable supply of high-quality biologics for commercial demand and clinical pipeline needs.
  • Maintain safety, quality, and efficiency standards across cell culture, purification, and manufacturing sciences and technology operations.
  • Drive technology transfer and scale-up of new processes to industrialize new biologic therapies while minimizing risk and optimizing time to market.
  • Serve as Campus Lead with end-to-end accountability for shared Site Engineering, Environmental Health & Safety, Security, and Facilities services and infrastructure supporting both business units.
  • Establish and chair a unified campus governance model and leadership forum to align priorities, resolve cross-business-unit resource and capacity trade-offs, and represent Devens to the enterprise.
  • Lead the multi-year integration of the GBU Biologics and Cell Therapy business units into a unified campus operating model.
  • Design and execute an integration roadmap covering organizational structure, ways of working, shared services, talent, and culture in partnership with GBU and Cell Therapy senior leadership.
  • Serve as the primary change agent for the transformation, building momentum, managing risk, and maintaining business continuity for both business units.
  • Champion a campus-wide safety and quality culture and ensure compliance with global GMP standards, EHS regulations, and regulatory requirements for biologics and cell therapy manufacturing.
  • Serve as the site’s executive sponsor during regulatory inspections and audits and maintain inspection readiness.
  • Model and enforce behaviors that prioritize patient safety, product quality, and a safe working environment.
  • Lead adoption of AI/ML, predictive analytics, automation, robotics, and other Industry 4.0 technologies to improve manufacturing efficiency, agility, and reliability and advance campus transformation.
  • Champion AI and advanced analytics for predictive maintenance, yield optimization, and proactive deviation management.
  • Partner with BMS Digital and IT teams to pilot and scale enterprise digital initiatives and ensure the workforce is trained to use digital tools.
  • Plan and execute major capital projects and technical upgrades, integrating modular facility design, single-use technologies, and automation to increase flexibility and throughput.
  • Oversee operational readiness for new facilities and equipment from commissioning through validation and ramp-up.
  • Improve operational processes using Lean and Six Sigma to drive productivity, reduce costs, and eliminate waste while protecting product quality and supply consistency.
  • Foster an inclusive, high-performance culture that attracts, develops, and retains talent across both business units.
  • Lead and mentor the site’s multidisciplinary leadership team and align functional areas around common goals.
  • Build a future-ready workforce with technical expertise in biologics and/or cell therapy and digital proficiency.
  • Manage the site’s P&L and financial performance for GBU Biologics operations and oversee the shared campus services budget.
  • Develop and oversee annual operating budgets and long-range financial plans, setting performance targets.
  • Track return on investment for capital projects, digital innovations, and integration initiatives and maintain financial controls and forecasting.
  • Serve as the key liaison between the Devens campus and government officials, regulatory agencies, industry associations, and the local community.
  • Engage with health authorities and support corporate social responsibility initiatives and environmental stewardship.
Desired Qualifications
  • Experience introducing and scaling new modalities from late-stage development into full commercial production.
  • Experience with cell therapy or other advanced/complex therapy manufacturing.
  • An advanced degree (M.S., Ph.D., or MBA), especially with specialization in biotechnology, pharmaceutical sciences, or business management.

About the company

Bristol Myers Squibb discovers, develops and sells prescription medicines for serious illnesses, including cancer, blood disorders, immune diseases and heart disease, for patients treated by doctors and hospitals around the world. Its best-known drug is Opdivo, an immunotherapy that helps the body's own immune system find and attack many kinds of cancer. Researchers develop drug candidates in its labs or bring them in through acquisitions and partnerships, then test them in clinical trials to win regulatory approval. The company makes and markets the approved medicines and earns its revenue from sales of patent-protected drugs. Its roots go back to a business founded in 1887, and it is based in Lawrence Township, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Lawrence Township, New Jersey

Founded

1887

Get referred to Bristol Myers Squibb

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sales are beating forecasts: BMS raised 2026 revenue guidance to $49 billion to $50 billion in July 2026.
  • Newer drugs carry the business: they made $7.6 billion of $13.0 billion in sales in the June 2026 quarter.
  • Manufacturing careers are expanding: a $2.3 billion Houston campus announced in August 2026 will add nearly 500 skilled roles.

What critics are saying

  • Job security is shaky: BMS added 265 New Jersey layoffs in September 2026, bringing its 2026 state cuts to 718.
  • A patent cliff looms: Eliquis and Opdivo, its two biggest drugs, lose US exclusivity around 2028.
  • Older drugs are shrinking fast: Revlimid sales fell 49% to $425 million in the June 2026 quarter as generics spread.

What makes Bristol Myers Squibb unique

  • BMS owns a psychiatry first: Cobenfy treats schizophrenia without blocking dopamine, unlike antipsychotics used for decades.
  • Its top seller is shared: BMS splits Eliquis blood thinner profits roughly equally with Pfizer in most markets.
  • BMS reengineers patients' own immune cells: it sells two CAR T therapies, Breyanzi and Abecma, for blood cancers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Hybrid Work Options
  • Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

7%

2 year growth

7%
Market Chameleon
Oct 19th, 2026
Bristol Myers to bring 12 oral presentations and nearly 60 oncology disclosures to ESMO 2026.

Bristol Myers to bring 12 oral presentations and nearly 60 oncology disclosures to ESMO 2026. 19 October 2026, 8:50 AM By Market Chameleon Produced with AI assistance and reviewed by Market Chameleon staff. Bristol Myers Squibb (BMY) said it will present new data across its oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) 2026 Congress (October 23-27 in Madrid), spanning 12 oral presentations and nearly 60 disclosures. The company's update spotlights multiple modalities across solid tumors, including late-breaking Phase 3 studies for izalontamab brengitecan (iza-bren) and late-breaking global Phase 2 data for pumitamig, alongside long-term survival results for Opdivo plus Yervoy. ESMO 2026 presence emphasizes late-breaking Phase 3 and Phase 2 catalysts across solid tumors. In the announcement, Bristol Myers highlighted two late-breaking, Phase 3 studies of izalontamab brengitecan (iza-bren), described as a potential first-in-class EGFR x HER3 bispecific antibody-drug conjugate (ADC), in EGFR-mutated non-small cell lung cancer (PANKU-Lung01) and HR+/HER2- breast cancer (PANKU-Breast01).

Savills
Oct 14th, 2026
San diego Q3 2026 life sciences market report.

San diego Q3 2026 life sciences market report. 14 October 2026 Market highlights. * Overall vacancy increased 60 basis points year over year to 28.5% in Q3 2026, up from 27.9% in Q3 2025. The increase was driven by direct vacancy, which rose to 25.8%, while sublease vacancy declined to 2.8%. * Venture capital funding slowed considerably in 2026, with $1.4 billion raised across 113 deals through Q3, down 34.1% year over year and marking the lowest Q1 through Q3 total since 2022. * Alexandria Real Estate delivered a 427,000-square-foot R&D hub for Bristol Myers Squibb at Campus Point, establishing the company as an anchor tenant at the 2.9- million-square-foot life sciences campus.

Yahoo Finance
Oct 13th, 2026
Eli Lilly beats Bristol Myers Squibb on growth: $65.2B revenue, 45% rise vs. $48.2B

A comparison of Bristol Myers Squibb and Eli Lilly concludes that Lilly is the better healthcare stock to buy in 2026, even at a premium. Lilly's 2025 revenue rose about 45% to $65.2 billion, with net income near $21 billion. Bristol Myers' revenue slipped 0.2% to $48.2 billion, though it returned to a net income of $7.1 billion after an $8.9 billion loss in 2024. Lilly trades at 33.8 times forward earnings against 8.2 times for Bristol Myers. The article says Bristol Myers is cheap for good reason, citing pricing pressure, patent expiries, and an unpredictable recovery. Lilly's weight-loss drugs Zepbound and Mounjaro are expected to lift 2026 revenue above 30%, to $88.6 billion. Bristol Myers is forecast to grow 3% to $49.9 billion.

Chinese LGZ
Oct 9th, 2026
Bristol Myers Squibb unveils $2.3 billion investment in cutting-edge Houston pharma facility.

Bristol Myers Squibb unveils $2.3 billion investment in cutting-edge Houston pharma facility. Source link: https://houston365.info/2026/10/09/bristol-myers-squibb-unveils-2-3-billion-investment-in-cutting-edge-houston-pharma-facility/ Bristol Myers Squibb strengthens Houston's life sciences sector with $2.3 billion facility. Bristol Myers Squibb is set to transform Houston's pharmaceutical landscape through a landmark $2.3 billion investment in a cutting-edge manufacturing plant. This initiative, developed in collaboration with the Greater Houston Partnership, aims to elevate the company's production capabilities while cementing Houston's status as a burgeoning center for biopharmaceutical innovation. The project is projected to generate hundreds of skilled jobs and stimulate substantial economic growth within the region. Project overview and strategic importance. The new facility will incorporate the latest manufacturing technologies to optimize efficiency and product quality. With over 1,200 new roles anticipated in scientific research, engineering, and production, the plant will serve as a catalyst for workforce development and community engagement. This expansion aligns with Bristol Myers Squibb's vision to accelerate the delivery of novel therapies and reinforces Houston's growing influence in the life sciences ecosystem. * Innovative manufacturing processes: Adoption of advanced automation and quality control systems. * Employment opportunities: Creation of more than 1,200 specialized jobs across multiple disciplines. * Community collaboration: Strengthening partnerships with local universities and healthcare institutions to foster innovation. | Investment Detail | Information | | Total... | - - Author: Samuel Brown Publish date: 2026-10-09 15:23:00 Copyright for syndicated content belongs to the linked Source. - - 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8

GlobeNewswire
Oct 6th, 2026
Sotyktu gains ground in Psoriatic Arthritis, but rheumatologists remain selective as its role in the treatment algorithm takes shape, according to Spherix Global Insights.

Sotyktu gains ground in Psoriatic Arthritis, but rheumatologists remain selective as its role in the treatment algorithm takes shape, according to Spherix Global Insights. New research finds growing prescriber adoption and enthusiasm for TYK2 differentiation, while limited experience, access friction, and questions around joint efficacy temper early launch momentum. Exton, PA, Oct. 06, 2026 (GLOBE NEWSWIRE) - Five months into the U.S. launch of Bristol Myers Squibb's (BMS) Sotyktu (deucravacitinib) for psoriatic arthritis (PsA), rheumatologists are increasingly adding the oral TYK2 inhibitor to their treatment armamentarium. Yet, new research from Spherix Global Insights suggests that broader trial has not yet translated into deep utilization, as physicians continue to refine where Sotyktu fits within an already crowded PsA treatment landscape. Findings from Spherix's latest wave of Launch Dynamix(TM): Sotyktu in Psoriatic Arthritis (US) reveal that 41% of rheumatologists have now prescribed Sotyktu, approximately double the proportion observed shortly after launch. However, depth of use remains limited, with new patient initiations slowing to their lowest level since launch and rheumatologists becoming increasingly selective in the proportion of PsA patients they consider appropriate candidates for the therapy. The pattern suggests that rheumatologists are willing to trial Sotyktu, but are doing so selectively as they gain experience with the product. Importantly, physicians have not written off the drug's longer-term potential. Despite selective use today, rheumatologists continue to anticipate a meaningful role for Sotyktu once fully established, with expectations holding relatively steady throughout the early launch period. A New Oral Option Is Finding Its Niche Sotyktu's novel TYK2 mechanism of action and expected efficacy remains the leading drivers of initiation, with its oral administration and perceived safety profile creating particular appeal for patients who wish to avoid injections or for whom JAK inhibitors may be less desirable. Indeed, nearly two-thirds of rheumatologists believe Sotyktu will expand their overall use of oral therapies in PsA, rather than simply replace another oral agent. This positioning is beginning to translate into a recognizable patient profile. Current Sotyktu use remains concentrated in moderate disease and third-line-or-later treatment, but first-line use has doubled since May, suggesting that some physicians are beginning to experiment with the drug earlier in the treatment journey. The result is an emerging position for Sotyktu somewhere between Otezla and traditionally more potent advanced therapies, an oral option that may appeal both to earlier patients seeking to avoid injectable biologics and to more heavily pretreated patients in need of another mechanism. "I've been using it, like a first-line agent, kind of like a stronger Otezla that has better data." one rheumatologist told Spherix. TYK2 Differentiation Resonates, but Joint Efficacy Remains a Question Rheumatologists appear to recognize meaningful differentiation in Sotyktu's TYK2 mechanism, with its oral profile, perceived safety, and efficacy contributing to an emerging position within the PsA treatment landscape. Early perceptions suggest the therapy may occupy a distinct space among existing oral and advanced treatment options without directly mirroring the profile of any one competitor. At the same time, early clinical experience is introducing some nuance. While physicians report positive experiences among many patients treated to date, questions around joint efficacy relative to established advanced therapies remain, suggesting that greater real-world experience may be important in determining how broadly rheumatologists ultimately use Sotyktu. A Quiet Launch May Be Limiting Momentum Beyond product perceptions, Spherix's findings point to commercial execution as another potential constraint on uptake. More than half of rheumatologists report that they have never interacted with a BMS sales representative for Sotyktu in PsA, and physicians interviewed by Spherix frequently characterized BMS's launch presence as relatively quiet compared with other recent rheumatology launches. Access also remains a friction point. Among recent Sotyktu initiations, 81% required prior authorization, although most were approved on the first attempt. TNF inhibitor failure remains the most common payer requirement. More broadly, rheumatologists' perception of Sotyktu access has become somewhat more restrictive since launch, with nearly one-third now characterizing payers as restricting access. Experience May Be the Next Inflection Point For now, Sotyktu appears to have cleared an important early hurdle: physicians are trying it. The next challenge will be converting that breadth of trial into greater depth of use. Limited familiarity and clinical experience remain the most frequently cited barriers to increased prescribing, while concerns about efficacy, particularly in more severe joint disease, have become more prominent as rheumatologists accumulate experience. Still, Sotyktu's differentiated mechanism, oral administration, and perceived safety advantages give the brand multiple potential paths to growth. With physicians continuing to project meaningful longer-term use, the coming months will help determine whether Sotyktu remains a selectively used alternative or establishes a broader role between Otezla and higher-potency advanced therapies. Launch Dynamix(TM): Sotyktu in Psoriatic Arthritis (US) is an independent Spherix Global Insights service tracking the launch of Sotyktu among U.S. rheumatologists. The August Deep Dive is based on quantitative research with 78 rheumatologists conducted August 5-8, 2026, supplemented by qualitative interviews with six rheumatologists conducted August 24-28. Launch Dynamix provides monthly benchmarking during the first 18 months of commercial availability, augmented by quarterly deep dives examining patient types, brand perceptions, promotional activity, and drivers and barriers to uptake. About Launch Dynamix(TM) Launch Dynamix(TM) is an independent service providing monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand. About Spherix Global Insights Spherix Global Insights is a leading independent provider of market intelligence and advisory services for specialty pharmaceutical and biotech markets. By combining physician, patient, and payer perspectives into an integrated view, Spherix helps brand teams, market access stakeholders, and investors understand how a specialty market actually behaves, not how any one stakeholder describes it. The firm operates ten dedicated therapeutic franchises - Dermatology, Gastroenterology, Hematology, Nephrology, Neuroscience, Obesity, Oncology, Ophthalmology, Respiratory and Rheumatology - plus a Market Access team. Each franchise is staffed by hyper-focused experts who track these markets full-time, drawing on independently curated communities of vetted specialists, patients, and payers to deliver quarterly trending, launch tracking, chart audits, and KOL synthesis. Trusted by 19 of the top 20 pharmaceutical and biotech organizations, Spherix has been a go-to resource for more than a decade for leading brands, industry media, financial analysts, and patient advocacy groups. To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com.